scispace - formally typeset
K

Karl Kunzelmann

Researcher at University of Regensburg

Publications -  310
Citations -  17209

Karl Kunzelmann is an academic researcher from University of Regensburg. The author has contributed to research in topics: Cystic fibrosis transmembrane conductance regulator & Chloride channel. The author has an hindex of 72, co-authored 293 publications receiving 15730 citations. Previous affiliations of Karl Kunzelmann include University of Queensland & University of California, San Francisco.

Papers
More filters
Journal ArticleDOI

CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells.

TL;DR: The successful establishment of a postcrisis SV40 large T-antigen transformed epithelial cell line derived from human bronchial epithelium is described, and this cell line, 16HBE14o- cells, provides a valuable resource for studying the modulation of CFTR and its role in regulation of chloride ion transport in human airway epithelia as well as other aspects of human airways cell biology.
Journal ArticleDOI

Electrolyte Transport in the Mammalian Colon: Mechanisms and Implications for Disease

TL;DR: Knowledge of the mechanisms of electrolyte transport in the colon enables the development of new strategies for the treatment of CF and secretory diarrhea and will lead to a better understanding of the pathophysiological events during inflammatory bowel disease and development of colonic carcinoma.
Journal ArticleDOI

Ion channels and cancer.

TL;DR: It will be an essential task for future studies to unravel cell cycle-specific effects of ion channels and non-specific homeostatic functions and overcome the shortcomings of some of the current approaches.
Journal ArticleDOI

TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression

TL;DR: A mechanistic analysis of the tumorigenic properties of TMEM16A is provided, which represents a potentially novel therapeutic target and the development of small-molecule inhibitors against TMEM 16A may be clinically relevant for treatment of human cancers, including SCCHN.